Cormedix (19KA) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

19KA Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Cormedix

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

19KA Stock 12 Month Forecast

Average Price Target

€12.46

▲(112.25% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Cormedix in the last 3 months. The average price target is €12.46 with a high forecast of €13.11 and a low forecast of €11.37. The average price target represents a 112.25% change from the last price of €5.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","9":"€9","14":"€14","6.5":"€6.5","11.5":"€11.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.1145591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.458831145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.36595122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€11.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.5,9,11.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.658,7.1546583923076925,7.651316784615385,8.147975176923078,8.64463356923077,9.141291961538462,9.637950353846154,10.134608746153846,10.631267138461538,11.12792553076923,11.624583923076923,12.121242315384615,12.617900707692307,{"y":13.1145591,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.658,7.104217780384616,7.550435560769231,7.996653341153847,8.442871121538461,8.889088901923078,9.335306682307692,9.781524462692307,10.227742243076923,10.67396002346154,11.120177803846154,11.566395584230769,12.012613364615383,{"y":12.458831145,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.658,7.020150093846154,7.382300187692308,7.7444502815384615,8.106600375384616,8.46875046923077,8.830900563076924,9.193050656923077,9.555200750769231,9.917350844615385,10.279500938461538,10.641651032307692,11.003801126153846,{"y":11.36595122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.172,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.908,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.658,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€13.11

Average Price Target€12.46

Lowest Price Target€11.37

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Les Sulewski

Truist Financial

―

Buy

―

Reiterated

05/15/26

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)

Roanna Ruiz

Leerink Partners

€12.24→€13.11

Buy

123.42%

Upside

Reiterated

05/15/26

Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA), Cormedix (NASDAQ: CRMD) and AnaptysBio (NASDAQ: ANAB)

Brandon Folkes

H.C. Wainwright

€11.37

Buy

93.63%

Upside

Reiterated

05/15/26

Analyst Reiterates Buy on Cormedix, Maintains Unchanged $13 Price Target Amid Strengthening Commercial Execution and Pipeline Prospects

Leonid Timashev

RBC Capital

€12.24

Buy

108.52%

Upside

Assigned

05/14/26

RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)

Serge Belanger

Needham

€13.11

Buy

123.42%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Immatics (NASDAQ: IMTX) and Cormedix (NASDAQ: CRMD)

Jason Kolbert

D. Boral Capital

€12.24

Buy

108.52%

Upside

Upgraded

10/20/25

CorMedix upgraded to Buy from Hold at D. Boral CapitalCorMedix upgraded to Buy from Hold at D. Boral Capital

Jason Butler

Citizens JMP

€19.23

Buy

227.68%

Upside

Reiterated

09/09/25

Cormedix (CRMD) Gets a Buy from Citizens JMP

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Les Sulewski

Truist Financial

―

Buy

―

Reiterated

05/15/26

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)

Roanna Ruiz

Leerink Partners

€12.24→€13.11

Buy

123.42%

Upside

Reiterated

05/15/26

Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA), Cormedix (NASDAQ: CRMD) and AnaptysBio (NASDAQ: ANAB)

Brandon Folkes

H.C. Wainwright

€11.37

Buy

93.63%

Upside

Reiterated

05/15/26

Analyst Reiterates Buy on Cormedix, Maintains Unchanged $13 Price Target Amid Strengthening Commercial Execution and Pipeline Prospects

Leonid Timashev

RBC Capital

€12.24

Buy

108.52%

Upside

Assigned

05/14/26

RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)

Serge Belanger

Needham

€13.11

Buy

123.42%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Immatics (NASDAQ: IMTX) and Cormedix (NASDAQ: CRMD)

Jason Kolbert

D. Boral Capital

€12.24

Buy

108.52%

Upside

Upgraded

10/20/25

CorMedix upgraded to Buy from Hold at D. Boral CapitalCorMedix upgraded to Buy from Hold at D. Boral Capital

Jason Butler

Citizens JMP

€19.23

Buy

227.68%

Upside

Reiterated

09/09/25

Cormedix (CRMD) Gets a Buy from Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cormedix

3 Months

Brandon FolkesH.C. Wainwright

Success Rate

8/11 ratings generated profit

Average Return

+15.44%

Copying Brandon Folkes's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +15.44% per trade.

1 Year

Jason ButlerCitizens JMP

Success Rate

17/24 ratings generated profit

Average Return

+51.88%

Copying Jason Butler's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +51.88% per trade.

2 Years

Jason ButlerCitizens JMP

Success Rate

18/24 ratings generated profit

Average Return

+63.55%

Copying Jason Butler's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +63.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

19KA Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 19KA has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 19KA average Analyst price target in the past 3 months is 12.46.

Each month's total comprises the sum of three months' worth of ratings.

19KA Financial Forecast

19KA Earnings Forecast

Next quarter’s earnings estimate for 19KA is €0.20 with a range of €0.13 to €0.27. The previous quarter’s EPS was €0.38. 19KA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 19KA has Performed in-line its overall industry.

19KA Sales Forecast

Next quarter’s sales forecast for 19KA is €83.60M with a range of €82.71M to €86.39M. The previous quarter’s sales results were €111.41M. 19KA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 19KA has Performed in-line its overall industry.

19KA Stock Forecast FAQ

What is DE:19KA’s average 12-month price target, according to analysts?

Based on analyst ratings, Cormedix Inc.’s 12-month average price target is 12.46.

What is DE:19KA’s upside potential, based on the analysts’ average price target?

Cormedix Inc. has 112.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Cormedix Inc. a Buy, Sell or Hold?

Cormedix Inc. has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Cormedix Inc.’s share price target?

The average share price target for Cormedix Inc. is 12.46. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €13.11 ,and the lowest forecast is €11.37. The average share price target represents 112.25% Increase from the current price of €5.87.

What do analysts say about Cormedix Inc.?

Cormedix Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Cormedix Inc.?

To buy shares of DE:19KA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Cormedix (19KA) Stock Forecast & Price Target

19KA Analyst Ratings

19KA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cormedix

19KA Analyst Recommendation Trends

19KA Financial Forecast

19KA Earnings Forecast

19KA Sales Forecast

19KA Stock Forecast FAQ

Detailed List of Analyst Forecasts